MCL1 and neoplasm: Preclinical data suggest synergistic anti-tumor effect of PV and venetoclax (inhibitor of anti-apoptotic Bcl-2 protein) when PV promotes MCL-1 (myeloid leukemia cell 1) degradation, a known mechanism of resistance to venetoclax (Ven) [32].